New Advances, Clinical Opportunities, and Current Challenges in Treating Adults With Ph-Negative ALL

Gain expert perspective on recent changes that are improving care for patients with acute lymphoblastic leukemia. Representative cases and slides will emphasize key data and provide the rationale for treatment decisions. 

Join us to fully interact, text, and contribute to the content and outcome of this event!

Friday Satellite Symposium preceding the 60th ASH Annual Meeting & Exposition.


6:30 PM Welcome and Program Overview

6:35 PM Case Discussion 1: Risk Stratification and New Advances in the Choice of Induction and Postremission Strategies

7:05 PM Case Discussion 2: Overcoming Treatment Challenges in Patients With Relapsed/Refractory ALL: Focus on Antibody–Drug Conjugates

7:40 PM Case Discussion 3: Overcoming Treatment Challenges in Patients With Relapsed/Refractory ALL: Focus on Bispecific T-Cell–Engaging Antibodies

8:15 PM Case Discussion 4: Overcoming Treatment Challenges in Patients With Relapsed/Refractory ALL: Focus on CAR-Engineered T-Cells

8:50 PM Clinical Trial Spotlight of Key Studies at ASH 2018

8:55 PM Conclusions and Final Question and Answer Session


Date / Time
Event Details


Program Chair
Susan O'Brien, MD

Associate Director for Clinical Science, Chao Family Comprehensive Cancer Center
Medical Director, Sue & Ralph Stern Center for Clinical Trials & Research
Professor, Division of Hematology/Oncology
School of Medicine
University of California, Irvine
Orange, California

Renier J. Brentjens, MD, PhD

Associate Professor
Department of Medicine
Weill Medical College of Cornell University
Associate Professor
Department of Pharmacology
Weill Cornell Graduate School of Medical Sciences
Associate Attending
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Aaron C. Logan, MD, PhD

Associate Professor
Division of Hematology and Blood and Marrow Transplantation
University of California, San Francisco
San Francisco, California

Matthew Wieduwilt, MD

Associate Clinical Professor of Medicine
Department of Medicine
Chair, University of California Hematologic Malignancies Consortium
University of California
San Diego, California

Goal Statement
The goal of this activity is to improve the competence and performance of physicians leading multidisciplinary care teams in applying the latest practice-changing developments to the clinical care of patients with acute lymphoblastic leukemia.

Target Audience 
This program is intended for physicians and other healthcare providers who care for patients with acute lymphoblastic leukemia.

Learning Objectives 

  • Discuss the clinical data on prognostic or predictive molecular features or aberrations in ALL and describe their clinical importance in terms of diagnosis, risk prediction, and therapeutic decisions
  • Evaluate the available evidence to optimally integrate antibody–drug conjugates and other immune-based therapies in ALL
  • Plan evidence-based induction and postremission strategies for specific patient populations, including those who are elderly or unfit
  • Develop personalized treatment plans for patients with relapsed/refractory ALL, considering the available clinical evidence and new drug approvals
  • Apply preventive as well as management strategies for treatment-related toxicities associated with novel therapeutics in ALL, including veno-occlusive disease and cytokine release syndrome
  • Identify patients with ALL who may benefit from enrollment on clinical trials evaluating novel immune-based combination therapies


Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.